PPARG and obesity disorder: To investigate whether ANXA1 affected mice obesity via PPARγ in vivo, we treated HFD-fed Anxa1AKO mice with GW9662 (intraperitoneal injection every other day at a dose of 1 mg/kg for 16 weeks).